Paclitaxel Given Once Per Week With or Without Bevacizumab in Patients With Advanced Angiosarcoma: A Randomized Phase II Trial Lenalidomide is an orally active immunomodulatory drug that has direct ...
Am J Health Syst Pharm. 2007;64(17):1799-1807. Despite a similar chemical structure to thalidomide, the toxicity profile of lenalidomide has been shown to be quite different. The major dose-limiting ...
A new study demonstrates that the combination of lenalidomide (Revlimid) and obinutuzumab (Gazyva) is effective and well-tolerated in treating relapsed indolent non-Hodgkin lymphoma (NHL). The trial, ...
A new study conducted by researchers from the Cancer Science Institute of Singapore (CSI Singapore) at the National University of Singapore has uncovered a key mechanism behind lenalidomide resistance ...
A new study conducted by researchers from the Cancer Science Institute of Singapore (CSI Singapore) at the National University of Singapore has uncovered a key mechanism behind lenalidomide resistance ...
Phase I data presented at the 2023 American Society of Hematology (ASH) annual meeting showed the benefit of lenalidomide (Revlimid) rechallenge in relapsed/refractory multiple myeloma patients ...
RIO DE JANEIRO — The addition of daratumumab to lenalidomide maintenance therapy following autologous stem cell transplant (ASCT) significantly improves rates of achieving minimal residual disease ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback